Biohaven Pharmaceutical
Presence
Portage Biotech is a company listed under the stock ticker PRTG (CA).
Portage Biotech has a direct presence in 3 countries.Portage Biotech has 3 subsidiaries including Biohaven Pharmaceutical, BioShin and Sentien Biotech.
They are in:
- Biotechnology75%
- Pharmaceuticals25%
Acquisition, funding and merger involving Portage Biotech.
- Pfizer has announced the acquisition of Biohaven Pharmaceutical (posted on May 12 2022).
Executives
View the org chart displaying its 121 main executives
Most searched biographies at Biohaven Pharmaceutical
- Vlad Coric, Chief Executive Officer and Chairman of the Board
- Bob Hugin, Director
- John Childs, Director
Create your alert
to follow the executive moves at Biohaven Pharmaceutical.
Pharmaceuticals
Portage Biotech has 1,867 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Biohaven Pharmaceutical
- Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
- Biohaven Announces Record Date for Anticipated Spin-Off
- Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
- Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
- American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
- Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
- Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
- Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray
- Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
- Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
- View more press releases Close
Social media about Biohaven Pharmaceutical
- Biohaven Pharmaceutical on Wikipedia, Google News & Yahoo Finance
- Biohaven Pharmaceutical on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Vlad Coric 
Call Biohaven Pharmaceutical at +1 203...
